The anti-NKG2D blocking antibody inhibited Gemcitabine-induced NK cell-mediated lysis as well as CD107a expression in NK cells against the A549 tumor target, while treatment with an isotype control antibody had no effect (Fig 6Ai and 6Aii), indicating that the Gemcitabine-induced NK cell-mediated cytotoxicity was dependent on NKG2D-NKG2D ligand interaction. The gene discussed is KLRK1; the disease is neoplasm.